Meeting
2020 Genitourinary Cancers Symposium
Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have completed first-line (1L) treatment (tx): Results from a cross-sectional real-world study.
Authors
Giovanni Zanotti
Pfizer Inc., New York, NY
Giovanni Zanotti , Ruth Kim , Stan Krulewicz , Jennifer P. Hall , Andrea Leith , Abigail Bailey , Frank Xiaoqing Liu , Mairead Kearney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 643)
Abstract #
643
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS.
First Author: Constance Thibault
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan
Poster
2021 ASCO Annual Meeting
Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).
First Author: Marc-Oliver Grimm
Poster
2019 ASCO Annual Meeting
Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).
First Author: Meredith M. Regan